









1706Peripheral Blood RNA Sequencing Unravels
a Differential Signature of Coding
and Noncoding Genes by Types of Kidney
Allograft RejectionSilvia Pineda1,2, Swastika Sur1, Tara Sigdel1, Mark Nguyen1, Elena Crespo3, Alba Torija3,
Maria Meneghini3,4, Montse Gomà5, Marina Sirota2,6, Oriol Bestard1,3,7 and
Minnie M. Sarwal1,7
1Division of Transplant Surgery, University of California San Francisco, San Francisco, California, USA; 2Bakar Computational
Health Sciences Institute, University of California San Francisco, San Francisco, California, USA; 3Laboratory of Experimental
Nephrology and Transplantation, Institut d’Investigació Biomèdica de Bellvitge, Barcelona, Spain; 4Kidney Transplant Unit,
Bellvitge University Hospital, Institut d’Investigació Biomèdica de Bellvitge, Barcelona, Spain; 5Pathology Department, Bell-
vitge University Hospital, Barcelona University, Institut d’Investigació Biomèdica de Bellvitge, Barcelona, Spain; and
6Department of Pediatrics, University of California San Francisco, San Francisco, California, USAIntroduction: Peripheral blood (PB) molecular patterns characterizing the different effector immune
pathways driving distinct kidney rejection types remain to be fully elucidated. We hypothesized that
transcriptome analysis using RNA sequencing (RNAseq) in samples of kidney transplant patients would
enable the identification of unique protein-coding and noncoding genes that may be able to segregate
different rejection phenotypes.
Methods: We evaluated 37 biopsy-paired PB samples from the discovery cohort, with stable (STA),
antibody-mediated rejection (AMR), and T cell–mediated rejection (TCMR) by RNAseq. Advanced machine
learning tools were used to perform 3-way differential gene expression analysis to identify gene signa-
tures associated with rejection. We then performed functional in silico analysis and validation by Fluidigm
(San Francisco, CA) in 62 samples from 2 independent kidney transplant cohorts.
Results: We found 102 genes (63 coding genes and 39 noncoding genes) associated with AMR (54
upregulated), TCMR (23 upregulated), and STA (25 upregulated) perfectly clustered with each rejection
phenotype and highly correlated with main histologic lesions (r ¼ 0.91). For the genes associated with
AMR, we found enrichment in regulation of endoplasmic reticulum stress, adaptive immunity, and Ig
class-switching. In the validation, we found that the SIGLEC17P pseudogene and 9 SIGLEC17P-related
coding genes were highly expressed among AMR but not in TCMR and STA samples.
Conclusions: This analysis identifies a critical gene signature in PB in kidney transplant patients under-
going AMR, sufficient to differentiate them from patients with TCMR and immunologically quiescent
kidney allografts. Our findings provide the basis for new studies dissecting the role of noncoding genes in
the pathophysiology of kidney allograft rejection and their potential value as noninvasive biomarkers of
the rejection process.
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idney transplantation remains the preferred treat-
ment for end-stage renal disease.1,2 However,
chronic immune-mediated allograft rejection, funda-
mentally driven by the humoral effector pathway of
adaptive immunity, remains the main cause of acceler-
ated graft loss.3,4 Recent clinical and experimental evi-
dence suggest that chronic AMR progressively appears
as a continuum process, preceded by T-cell immune
activation, which can lead to clinical or subclinicalKidney International Reports (2020) 5, 1706–1721
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCHTCMR.5–8 While the downstream effector mechanisms
of rejection seem to be compartmentalized and driven
by specific effector immune pathways, such as alloreac-
tive T cells and donor-specific antibodies (DSAs), a
broader activation of the alloimmune response is more
likely to occur during the rejection process.9–11
Currently, while different rejection phenotypes have
been classified according to defined histologic changes
in kidney transplant biopsy specimens, such patho-
logic lesions are not highly specific as no histology-
independent biopsy diagnostic system has been fully
validated yet.4–6 Therefore, the study of the underly-
ing molecular mechanisms of different histologic injury
patterns using genome-wide gene expression on kidney
allograft biopsy specimens has gained considerable
interest to more precisely characterize the different
pathologic processes of transplant rejection.10,12–16
Notably, the evaluation of the different molecular
mechanisms of allograft rejection has been also inves-
tigated in PB, in an attempt to better characterize the
distinct effector immune pathways leading to allograft
rejection while avoiding an invasive tissue allograft
assessment.17
The majority of the blood-based differential gene
expression studies have found common PB signatures
of rejection, but transcriptional profiling with cDNA10
and oligo-based microarrays14,15,18 as well as other
unbiased approaches, such as proteomics,7,8,18 protein
arrays,19 and transcriptional profiling10,14,15,18,20,21
have not been able to discern specific molecular vari-
ations distinguishing between different rejection phe-
notypes, because many rejections show combined
pathologic features of both TCMR and AMR, the so-
called mixed rejections. For instance, AMR tran-
scripts have been identified from biopsy specimens to
be strongly regulated by interferon-g,22 but a similar
axis of interferon-g regulation has also been identified
in TCMR and mixed rejections in PB.18 Therefore,
while previous published transcriptional studies have
allowed for a better understanding of the overall
biology of kidney transplant rejection, distinct differ-
ences in molecular pathways regulating TCMR and
AMR have been difficult to dissect in any biologically
meaningful manner.
We hypothesized that some of the difficulty in
identifying specific PB features of AMR, distinct from
TCMR, may relate to the specific differences, possibly
resulting in changes in microRNAs or long noncoding
RNAs, which are not usually measured by standard
microarray technologies. With this in mind, we con-
ducted RNAseq on unique biopsy-matched PB samples
with the aim to conduct transcriptome analysis at much
greater resolution because RNAseq allows for theKidney International Reports (2020) 5, 1706–1721differentiation between protein-coding genes and
noncoding genes, including pseudogenes, microRNA,
and long noncoding RNA.23–25 The aim of this
approach was to gain a more granular view of the
possible mechanisms of the main gene pathways of the
adaptive and innate immune responses in PB during an
active rejection episode in the graft, specific to either
TCMR or AMR, compared with immunologically
quiescent stable kidney transplant patients.METHODS
Patients
One hundred kidney transplant patients were evaluated
in this study. A first cohort of 37 consecutive adult kidney
transplant recipients undergoing either for-cause or sur-
veillance biopsy procedures between January 2014 and
December 2015 at Bellvitge University Hospital (Barce-
lona, Spain) were enrolled in the study. Three different
groups of patients were categorized according to the his-
tologic diagnosis made by a blinded expert transplant
pathologist following the updated Banff 2017 classifica-
tion26: patients with pure acute TCMR (n ¼ 13), patients
with AMR (n¼ 12), and patients with a normal/preserved
kidney allograft parenchyma (STA, n ¼ 12). All blood
samples were obtained at the time of the kidney allograft
biopsy procedure and before any immunosuppression
rescue therapy was given. Subsequently, 63 additional
kidney transplant patients from 2 distinct transplant
centers undergoing consecutive for-cause or surveillance
biopsy procedures between January 2017 and October
2018 were evaluated for targeted mRNA expression of
most representative noncoding and coding-related genes
observed in the first discovery cohort of patients. From
this second cohort, 33 patients were from Bellvitge Uni-
versityHospital, Barcelona, Spain (validation cohort I) and
29 patients were from University California San Francisco,
San Francisco, USA (validation cohort II). In the first
validation cohort (I), the main histologic diagnoses in for-
cause biopsy procedures were TCMR (n ¼ 10) and AMR
(n¼ 9), whereas 8 patients were evaluated in surveillance
biopsy procedures and were classified as STA (n¼ 15). In
the second validation cohort (II), the main histologic di-
agnoses were STA (n ¼ 12), AMR (n ¼ 7), and mixed re-
jections (n ¼ 10). Each biopsy specimen was scored by a
site’s specialist pathologist blinded for any result of the
transcriptional study. The main clinical, immunologic,
and histologic characteristics are shown in Supplementary
Table S1. All patients in the studywere receiving the same
triple immunosuppressive-based therapywith tacrolimus,
mycophenolate mofetil, and prednisone. All patients
evaluated in the study gave written informed consent to
participate and the institutional review boards at Bellvitge1707
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney RejectionUniversity Hospital (PR228/13) and the University of
California–San Francisco approved the study (14-13573).Renal Allograft Histology
Kidney allograft biopsy procedures were performed for
cause because of kidney allograft dysfunction in all
patients with TCMR and AMR rejection, whereas STA
patients showed stable allograft function and a pre-
served graft parenchyma in 6-month surveillance bi-
opsy procedures. All renal biopsy specimens were
analyzed following the Banff 2017 score classification26
and the histologic analysis was blindly evaluated by an
expert renal pathologist at each center before submit-
ting samples for molecular evaluation. Details are
shown in Supplementary Methods.Statistical Analysis
We performed differential expression (DE) analysis to
find those genes associated with the outcome. We
applied DESeq227 with a binomial distribution in all
pairwise combinations (AMR vs. STA, TCMR vs. STA,
and AMR vs. TCMR) and Elastic Net (ENET)28 with a
multinomial distribution for the 3-way comparison
(AMR vs. TCMR vs. STA). With the results from ENET
we performed a network analysis to show the associa-
tion between each gene and each of the clinical vari-
ables using a linear regression model and we
represented the final network using the Fruchterman-
Reingold layout,29 and finally we performed a linear
regression model to find those protein-coding genes
associated with each noncoding gene and gene
ontology (GO) annotations to predict the potential
function of the noncoding RNA genes.
For comparison with previously published micro-
array analysis, we also applied ENET to find genes
differential expressed between rejectors (AMR plus
TCMR) and STA. For this validation, we compared our
results with 2 lists of previously published differen-
tially expressed genes between STA and rejections
(Supplementary Table S2). One is the list of 2382
differentially expressed genes (false discovery rate
[FDR] < 0.05) identified in 4 different datasets using 3
different microarray platforms measured in either
whole blood or PB mononuclear cells15 and the other is
the list of 2977 identified probesets belonging to 1907
genes in PB in adult kidney transplant patients asso-
ciated with kidney rejection.14
For the validation cohorts, we used 1-way analysis of
variance to determine significant differences between
groups and we used the Tukey multiple comparison
test to compare the difference between each pair of
means. Further details of the statistical analyses are
found in the Supplementary Material and Methods.1708RESULTS
Clinical and Histologic Characteristics of the
Discovery Cohort
To understand the fundamental molecular mechanisms
underlying each histologic phenotype, we used RNA-
seq to profile unique blood samples from 37 consecu-
tive kidney transplant patients, classified in 3 specific
clinical phenotypes: STA (n ¼ 12), AMR (n ¼ 12), and
TCMR (n ¼ 13). The baseline clinical characteristics of
this patient cohort is shown in Table 1. Patients with
TCMR and AMR showed worse allograft function than
STA patients who showed a good and stable kidney
allograft function. Only patients with AMR displayed
DSA. TCMR Banff30 scores ranged between IA and IIA
(6 IA, 6 IB, and 3 IIA).
In Table 2, all semiquantitative histology scores
defining the distinct clinicopathologic groups of the
study are described. Each of these histologic measures
and time posttransplant were assessed as correlates in
the context of RNAseq data.Differentially Expressed Genes Classify Patients
into the 3 Clinical Phenotypes
We performed DE analysis between the 2 types of
rejection phenotypes and STA patients using RNAseq
first on only coding and after adding the noncoding
genes. We initially considered both types of rejection as
a single outcome (REJ) and then considered AMR and
TCMR separately, addressing all possible comparisons.
Subsequently, a 3-way comparison analysis was per-
formed. We used both DESeq227 and ENET28 for these
analyses. As shown in Table 3, based on the Jaccard
index (JI), ENET, which is a penalized technique that
considers the correlation structure between the vari-
ables, classified all the samples more accurately than
DESeq2, suggesting the importance of considering the
correlation structure between the genes. When non-
coding genes were added, the results significantly
improved not only increasing the JI but also lowering
the number of genes selected to classify the outcome,
highlighting the importance of noncoding genes in the
rejection process. When all the patients who rejected
were grouped together (REJ) within 1 category, neither
DESeq2 nor ENET were able to properly classify the
data, whereas when separated according to the rejection
phenotype (AMR or TCMR) the differences were
significantly stronger, especially when using the 3-way
comparison, where ENET found 102 genes (63 coding
and 39 noncoding genes) associated with AMR (54
upregulated), TCMR (23 upregulated), and STA (25
upregulated) showing 3 main clusters with a JI of 1.
Figure 1 shows a heat map and a cluster plot of the 3-way
comparison analysis. Theheatmaps showing the results ofKidney International Reports (2020) 5, 1706–1721








n [ 12 P value
Donor age, yr  SD 61.5  14.09 43.2  21.92 50.6  17.24 0.048
Recipient age, yr  SD 62.2  12.25 45.7  15.26 55.3  11.98 0.013
Recipient sex, female, n (%) 5 (38.5) 4 (33.3) 5 (41.7) 0.91
Donor sex, female, n (%) 8 (61.5) 5 (41.7) 5 (41.7) 0.51
Cause of ESRD, n (%) 0.55
Unknown 6 (46) 3 (25) 5 (36)
Glomerular 4 (31) 5 (42) 2 (16.7)
Interstitial 0 (0) 2 (17) 1 (8.3)
Vascular 1 (7.7) 1 (8.3) 2 (16.7)
Diabetes 2 (15.4) 0 (0) 1 (8.3)
APKD 0 (0) 0 (0) 1 (8.3)
Others 0 (0) 1 (8.3) 0 (0)
Type of transplant, died, n (%) 10 (77) 11 (91.7) 11 (91.7) 0.46
No. of transplants  SD 1.15  0.38 1.6  0.79 1.17  0.39 0.1
1 vs. >1, n (%) 11 (85) 7 (58) 10 (83) 0.23
No. HLA antigen mismatch  SD 3.0  0.95 3.58  0.9 3.25  1.3 0.41
Induction type, n (%) 0.064
None 0 (0) 2 (16.7) 1 (8.3)
Anti-CD25 mAb 10 (76.9) 4 (33.3) 10 (83.3)
rATG 3 (23.1) 6 (50.0) 1 (8.3)
DSA at biopsy (yes), n (%) 0 12 (100) 0 <0.001
Class I 3
ClassII 7
Class I and II 2
eGFR at biopsy, ml/min  SD 30.1  20.42 28.8  20.9 49.7  14.42 0.016
Proteinuria at biopsy, g/24 h  SD 0.76  0.9 1.79  1.37 0.19  0.23 0.001
Graft loss after biopsy assessment, n (%) 4 (30.8) 8 (66.7) 1 (8.3) 0.01
Time to biopsy, months  SD 4.8  3.8 91.6  83.1 6.8  2.4 <0.001
AMR, antibody-mediated rejection; APKD, autosomic polycystic disease; DSA, donor-specific antibody; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HLA,
human leukocyte antigen; mAb, monoclonal antibody; rATG, rabbit antithymocyte globulin; STA, stable; TCMR, T cell–mediated rejection.
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCHall comparisons made are shown in Supplementary
Figures S1–S10 and Supplementary Table S3. To test for
possible overfitting with ENET using a multinomial dis-
tribution, we performed a permutation test shuffling the
clinical outcome 10 times and applying exactly the same
strategy aswith the original data.None of thepermutations
had accurate results with amean JI of 0.27 (Supplementary
Figure S11). Finally, to test whether time to biopsy pro-
cedure was a confounding factor for the gene expression
signature reported here, we applied the same method
(ENETwith a multinomial distribution) to the samemodel,
adding this variable. The results remain the same with the
same 102 genes selected (Supplementary Table S4).Comparison of RNAseq Data and Microarray
Data in Kidney Allograft Rejection
We then compared the 1094 coding genes detected by
DESeq2 package (Table 3) with those identified in
previous published microarray studies using the same
FDR (<5%) between rejection and stable patients. Of
the 2382 differentially expressed genes identified in 3
different microarray platforms from 4 different dataKidney International Reports (2020) 5, 1706–1721sets evaluated in either peripheral blood mononuclear
cells or whole blood,15 225 genes were also present in
our analysis. Of the 1907 identified genes in PB in adult
kidney transplant patients developing kidney allograft
rejection,14 183 genes were also observed in our work.
The list of 1094 genes with the validated ones are
shown in Supplementary Table S5. However, even
though we showed that by grouping all the patients
who rejected into 1 single group does not result in
clean differentiation between AMR and TCMR by
microarray-based transcriptional profiling, the over-
lapping rejection-specific genes detected in PB, across
multiple datasets, using different platforms and patient
samples, supports the quality and biological validity of
the current dataset and analytics.Network Analysis Finds Association Between
the Differentially Expressed Genes and the
Fundamental Histologic Lesions of Allograft
Rejection
The 102 genes found to be associated with AMR,
TCMR, and STA were also associated with the1709
Table 2. Main histologic lesions of the patients of the study
Mean Banff scores in all
kidney graft compartments
Histologic phenotypes
TCMR, n [ 13 AMR, n [ 12 STA, n [ 12 P value
Acute lesions
Ag 0.8  0.8 1.5  0.9 0.2  0.4 <0.001
Ai 2.1  0.8 1.1  0.7 0.2  0.6 <0.001
at 2.3  0.6 0.8  0.5 0.5  0.9 <0.001
ti 2.1  0.9 1.4  0.8 0.2  0.4 <0.001
ptc 0.5  1.0 1.0  0.8 0.09  0.3 0.030
av 0.2  0.8 0.2  0.4 0.08  0.3 0.81
C4d 0.1  0.4 1.7  1.0 0.1  0.6 <0.001
Chronic lesions
cg 0.08  0.3 1.7  1.3 0.08  0.3 <0.001
ci 0.8  0.4 1.5  0.8 0.8  0.8 0.03
ct 0.7  0.5 1.7  0.7 0.8  0.8 0.001
cv 0.3  0.5 0.7  0.9 0.2  0.6 0.15
ah 0.1  0.5 1.1  1.2 0.2  0.6 0.01
cm 0  0 0.9  1.1 0.08  0.3 0.002
ag, acute glomeruli; ah, arterial hyalinosis; ai, acute interstitium; AMR, antibody-
mediated rejection; at, acute tubuli; av, acute vascular; cg, chronic glomeruli; ci,
chronic interstitium; Cm, chronic mesangial; ct, chronic tubuli; cv, chronic vascular; ptc,
peritubular capillaritis; STA, stable; TCMR, T cell–mediated rejection ti, total interstitial
inflammation.
TCMR: at, ai, av, and cv.
AMR: ag, ptc, c4d, cg, and cv plus donor-specific antibody/antiHLAb.
Interstitial fibrosis tubular atrophy: ci and ct.
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney Rejectionfundamental histologic lesions defining each clinical
phenotype, time to biopsy procedure, and DSA.
Figure 2 shows the correlation matrix among all these
parameters. As expected, histologic chronic lesions
(chronic vascular, chronic tubuli, chronic interstitium,
chronic glomeruli, arterial hyalinosis, and chronic
mesangial) correlated between them and with DSA and
time to biopsy procedure. Regarding acute histologic
lesions, 2 main correlation networks were observed, 1
clustering the acute tubuli, acute interstitium, and total
interstitial inflammation lesions and another at the
acute vascular, peritubular capillaritis, acute glomeruli,
and C4d lesions. The latter net did also correlate with
DSA and chronic glomeruli, which altogether defined
the clinical phenotype AMR. Also, chronic interstitium
and chronic tubuli lesions, defining IFTA, showed the
highest correlation (r ¼ 0.91).
For the association analysis, we performed a linear
model between each of the 102 genes and allTable 3. Differentially expressed genes for all the possible comparisons
coding genes and the addition of noncoding genes
Method Gene list REJ vs. STA
ENET (optimal alpha, lambda by CV) Coding plus noncoding 36 (0.47)
Coding 328 (0.43)
DESeq2 (FDR < 0.05, |FC| > 1.5) Coding plus noncoding 1176 (0.40)
Coding 875 (0.40)
DESeq2 (FDR < 0.05) Coding plus noncoding 1391 (0.40)
Coding 1094 (0.40)
AMR, antibody-mediated rejection; FC, fold change; FDR, false discovery rate; REJ, rejection (
aJaccard index measures the similarity of the samples within the same category. Closer to 1
1710fundamental histologic parameters, time to biopsy
assessment, and DSA. Those that passed a FDR
threshold of 0.05 were plotted in a network using the
Fruchterman-Reingold layout (Figure 3). We observed
3 networks in the correlation matrix: 1 main gene
cluster associated with main chronic histologic lesions
(chronic glomeruli, chronic interstitium, chronic
tubuli, chronic vascular, arterial hyalinosis, and
chronic mesangial), time to biopsy assessment, and
DSA. Interestingly, we observed that the genes that
were upregulated in AMR (AP4S1, ARMCX4, BTD,
CACHD1, CDK11B, DMAP1, ELF3, LA16c-360A4.1,
LINC00298, LINC01278, LRIG1, MFSD6L, MPP7,
NECAB3, P2RX5-TAX1BP3, PARD6G-AS1, RAB30,
RN7SL246P, RP11-1008M1.1, RP11-133M8.3, RP5-
1107A17.4, RPL4P6, SEPT2, SETDB2, SUPT5H,
SYVN1, TADA3, TP53BP1, UBAC2, UC_338, USP21,
and ZMYF841) were positively associated with these
clinical parameters, whereas those upregulated in
TCMR and STA were negatively associated with them.
Furthermore, the acute histologic lesions acute
glomeruli, peritubular capillaritis, and C4d were also
close to this main cluster as also shown in the corre-
lation matrix, but they also shared genes with the other
cluster made by acute tubuli, acute interstitium, and
total interstitial inflammation lesions. Notably, the
genes associated with this cluster were positively
associated with those upregulated in TCMR, such as
AK9, RAD23B, RPP21, RP11-43N22.1, UCN, S100A5,
RP11-392P7.6, MERTK, and ACTR3B, and negatively
associated with those upregulated in STA, and few of
them were associated with AMR. The parameter acute
vascular was not associated with any gene. The set of
genes associated with the different clinical and histo-
logic parameters is shown in Supplementary Table S6.
Functional Annotation of Differentially
Expressed Genes Using GO Biological Terms
We annotated the 102 genes DE by the 3 different
phenotypes (AMR, TCMR, and STA) with the GO
biological terms using the platform FUMA.31,32 We
included separately the 54 genes upregulated in AMR(pairwise and 3-way) using DESeq2 and ENET and considering only
Differentially expressed genes (Jaccard indexa)
AMR vs. STA TCMR vs. STA AMR vs. TCMR AMR vs. TCMR vs. STA
59 (1) 1 (–) 23 (1) 102 (1)
50 (1) 1 (–) 1073 (0.64) 131 (0.68)
4774 (0.55) 0 (–) 2099 (0.50) —
3541 (0.55) 0 (–) 1739 (0.50) —
5482 (0.55) 0 (–) 2244 (0.50) —
4221 (0.55) 0 (–) 2092 (0.50) —
AMR plus TCMR); STA, stable; TCMR, T cell–mediated rejection.
means more similar, closer to 0 means more different.
Kidney International Reports (2020) 5, 1706–1721
Figure 1. (a) Heatmap showing the 102 genes selected by Elastic Net (ENET) using a multinomial distribution. The selection is based on the
optimal alpha and lambda parameter using cross-validation. (b) Cluster plot showing the similarity between the samples using the 102 genes
selected by ENET. Cluster 1 classifies the T cell–mediated rejection patients (blue), cluster 2 the antibody-mediated rejection patients (red), and
cluster 3 the stable patients (green). The color scale shown in the heatmap matrix represents the differential expression normalized by column
to show the differences by samples per gene.
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCHand the 23 upregulated in TCMR. We found several
enriched GO terms (FDR < 0.05) involving 13 over-
lapping genes that were upregulated in AMR (SYVN1,
UBAC2, DMAP1, SETDB2, TP53BP1, TADA3, USP21,
SUPT5H, CDK11B, SEPT2, RAB30, STC17, and
DACT1; Table 4). All of the GO terms might be
grouped by similarity into 3 main groups: regulation of
protein stability, Golgi organization, and protein acet-
ylation. We also found significant enriched GO terms
(FDR < 0.05) using the upregulated genes in TCMR
with 13 overlapping genes (CMTM3, HCST, MERTK,
LGALS1, PSBM1, ANGPT1, UCN, AK9, DCTPP1,
ARPP19, SNRPF, RAD23B, and ZNF354A; Table 5),
which are grouped by similarity in immune system
development, regulation of transference activity, pro-
tein phosphorylated, cellular macromolecular complex
assembly, and response to organic cyclic compound.
ANGPT1, which belongs to the angiopoietin family, is
shared among the majority of all GO terms in TCMR.Kidney International Reports (2020) 5, 1706–1721Functional Annotation Inferred for Noncoding
DE Genes
We next investigated whether noncoding RNA also
influenced the different clinical phenotype and its as-
sociation with coding RNAs based on the idea of co-
expression matrix as previously done by others.33–35
As shown in Figure 4 in a Circos plot, we found 529
coding–noncoding associations (linear regression
model, FDR < 0.05) among the 102 DE genes associated
with the different clinical phenotypes (Supplementary
Table S7). The order of the genes shown in the plot
represents the cumulative effect size of their relation-
ships; RP5-1107A17.4, TRDC, and LINC01278 are the
noncoding genes with the larger effect size and
PSMB1, CACHD1, and SEPT2 are the coding genes
with larger effect size. Notably, PSMB1 was also shared
among many GO terms enriched in the upregulated
genes in TCMR. Since coding and noncoding genes
were strongly associated, we subsequently evaluated1711
Figure 2. Correlation matrix for all fundamental histologic lesions, donor-specific antibodies, and time to biopsy procedure. The coefficients
belong to a Pearson correlation and are colored if the P value is significant (< 0.05).
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney Rejectionthe functionality of the noncoding genes, by inferring
the function of the respective associated coding gene
through enriched GO biological terms (FDR < 0.05). As
shown in Supplementary Table S8, we observed that
most noncoding genes with an inferred GO biological
term were upregulated in AMR (RP5-1107A17.4,
LINC01278, RPL4P6, LINC00299, PARD6G-AS1,
LA16c-360A4.1, AP000936.1, SIGLEC17P, LINC00298,
AC159540.14, and RP11-1008M1.1), but 1 noncoding
gene (RP11-644F5.11) that was upregulated in TCMR
and none in STA. All these genes shared the common
term regulation of transcription, DNA templated (GO
0006355) and were associated with the same coding
genes (CDK11B, DACT1, DMAP1, ELF3, SETDB2,
SUPT5H, TADA3, TP53BP1, USP21, ZMYM6,
ZNF138, ZNF354A, ZNF436, and ZNF841) from which
5 of 14 belong to zinc finger transcriptional activators.
Characterization of Noncoding Genes and
Related Coding Genes in 2 Distinct Cohorts of
Kidney Transplant Patients
From our RNAseq in biopsy-matched PB samples of
kidney transplant patients, we identified unique1712protein-coding and noncoding genes. We next aimed at
characterizing these targeted mRNA of noncoding
genes and related coding genes in 2 additional kidney
transplant cohorts displaying a variety of kidney graft
histologic phenotypes according to the last Banff clas-
sification.4,26 We investigated the pseudogene sialic
acid–recognizing Ig-like lectins 17P (SIGLEC17P) and 9
SIGLEC17P-associated coding genes, the natural killer
(NK)–related transcript (NCAM1/CD56) because of its
association with SIGLEC17P and a highly upregulated
coding gene associated with B-cell Ig class switch
recombination (TP53BP1). We selected the noncoding
SIGLEC17P gene because though it is a noncoding gene
it is still highly expressed in high levels in NK cells,
which is widely accepted to mediate AMR. SIGLECs 13
and 17 were rendered nonfunctional during Hominin
evolution. While SIGLEC 17P underwent a single base
pair deletion in humans, they are still preserved in
chimpanzees and other new world monkeys. The
SIGLEC 17P’s mRNA are still widely expressed in NK
cells. This gene was significantly enriched in the
common GO term and is also found to be upregulated
in AMR (downregulated in TCMR) in our RNAseq data.Kidney International Reports (2020) 5, 1706–1721
Figure 3. Network plot showing the association between the 102 genes and the fundamental histologic lesions. The vertex represents the genes
belonging to each cluster shown in Figure 1 and the histologic lesions and the edges link those that were associated with a false discover
rate < 0.05 in a linear regression model. The width of each line represents the statistical significances (log10 P value) and the color whether
they are positively associated (gray) or negatively associated (orange).
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCHTherefore, such an association is less likely to be
coincidental, so we selected SIGLEC17P over other
noncoding genes. In cohort II (Figure 5a), expression of
SIGLEC17P was also significantly upregulated in AMR
patients compared with TCMR and STA. Notably, the 9
coding genes associated with SIGLEC17P (AP4S1,
ZMYM6, USP21, DMAP1, SUPT5H, TP53BP1,
NECAB3, BTD, and DACT1) were also found to be
highly upregulated in AMR compared with TCMR and
STA. Likewise to SIGLEC17P, the matured NK cell
specific marker NCAM1/CD56 as well as the B cell–
related protein coding gene TP53BP1 were also found
to be significantly overexpressed in AMR compared
with TCMR and STA. Likewise, in cohort III
(Figure 5b) the expression of SIGLEC17P was found toKidney International Reports (2020) 5, 1706–1721be upregulated in AMR than STA but not than mixed
rejections. Out of the 9 coding genes highly associated
with SIGLEC17P, only BTD and ZMYM6 could be
assessed in cohort III. As shown, they were also
significantly upregulated in AMR compared with STA
but not to mixed rejections.DISCUSSION
While an important body of evidence suggests the
preponderant role of the alloimmune response driving
kidney graft injury and ultimately graft loss, the main
molecular mechanisms participating in the rejection
process are still poorly understood. Herein, using
RNAseq analysis of PB samples timed with allograft1713
Table 4. GO biological terms for the functionality of the upregulated genes in antibody-mediated rejection
GO biological term FDR
Overlapping genes
SYVN1 UBAC2 DMAP1 SETDB2 TP53BP1 TADA3 USP21 SUPT5H CDK11B SEPT2 RAB30 STX17 DACT1
Negative regulation of response to endoplasmic
reticulum stress (GO 1903573)
0.04 X x
Peptidyl lysine modification (GO 0018205) 0.04 X x x x
Chromatin modification (GO 0006325) 0.04 X x x x x
Covalent chromatin modification (GO 0016569) 0.04 X x x x
Mitotic nuclear division (GO 0140014) 0.04 x x x x
Chromatin organization (GO 0006325) 0.04 X x x x x
Golgi organization (GO 0007030) 0.04 x x
Regulation of protein stability (GO 0031647) 0.04 X x x
Positive regulation of protein import (GO 1904591) 0.04 x x
Organelle fission (GO 0048285) 0.04 x x x x
Regulation of mRNA metabolic process (GO 1903311) 0.04 x x
Positive regulation of nucleocytoplasmic transport
(GO 0046824)
0.05 x x
Protein acetylation (GO 0006473) 0.05 x x
FDR, false discovery rate; GO, gene ontology.
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney Rejectionkidney transplant biopsy spciemens we show that
different biological processes govern the T- and B-cell
effector mechanisms triggering allograft rejection,Table 5. GO biological terms for the functionality of the upregulated gene
GO biological term FDR CMTM3 HCST MERTK LG
Regulation of immune system process (GO 0002684) 0.01 x x x
Positive regulation of cell communication (GO 0010647) 0.01 x x
Phosphorylation (GO 0016310) 0.01 x x
Positive regulation of response to stimulus (GO 0048584) 0.01 x x
Phosphate containing compound metabolic process
(GO 0006796)
0.01 x x
Regulation of immune response (GO 0050776) 0.01 x x
Positive regulation of transport (GO 0051050) 0.01 x
Protein phosphorylation (GO 0006468) 0.01 x x
Immune system development (GO 0002520) 0.01 x
Positive regulation of transferase activity (GO 0051347) 0.01
Negative regulation of protein modification process
(GO 0031400)
0.01
Cellular macromolecular complex assembly (GO 0034622) 0.02
Macromolecular complex assembly (GO 0065003) 0.02
Regulation of cell death (GO 0010941) 0.03 x
Positive regulation of immune system process (GO 0002684) 0.03 x
Multi organism reproductive process (GO 0044703) 0.03 x
Negative regulation of cell death (GO 0060548) 0.03 x
Positive regulation of intracellular signal transduction
(GO:1902533)
0.03 x
Response to organic cyclic compound (GO 0014070) 0.03
Regulation of transferase activity (GO 0051338) 0.03
Negative regulation of multicellular organismal process
(GO 0051241)
0.04
Regulation of protein modification process (GO 0031399) 0.04
Catabolic process (GO 0009056) 0.04
Regulation of transport (GO 0051049) 0.04 x
Negative regulation of protein metabolic process
(GO 0051248)
0.04
Response to external stimulus (GO 0009605) 0.05 x
Locomotion (GO 0040011) 0.05 x x
Positive regulation of protein modification process
(GO 0031401)
0.05
FDR, false discovery rate; GO, gene ontology.
1714which are otherwise believed to be both clinically and
pathologically diverse processes, thus requiring com-
plete different rescue immunosuppressive therapies.36s in T cell–medicated rejection
Overlapping genes
ALS1 PSMB1 ANGPT1 UCN AK9 DCTPP1 ARPP19 SNRPF RAD23B ZNF354A
x x x X
x x x X
x x x
x x x X
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Figure 4. Circos plot showing the 529 significant associations (false discovery rate < 0.05) selected from the 102 coding and noncoding genes
obtained in the differential expression analysis using ENET. The links represent each association between the coding and the noncoding genes.
The coding genes (from left to right) and the noncoding genes (from right to left) are ordered by the sum of effect size.
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCHMost importantly, using advanced machine learning
techniques, we show the relevance of including the
noncoding genes in the analysis to find biological
pathways discriminating both types of rejections. The
robustness of our findings is further sustained by the
characterization of these transcripts in 2 distinct co-
horts of kidney transplant patients displaying the same
histopathologic lesions compatible with AMR.
Previous gene expression studies14,15,18 show a
slightly overlap with our results. The fact that previous
analyses are only focused on coding genes and acuteKidney International Reports (2020) 5, 1706–1721rejection as a whole make it difficult to find robust
differences in pathways and biomarkers that clearly
distinguish TCMR and AMR by PB analysis alone, as
shown here. Moreover, the technologies used are
completely different because our analysis is based on
RNA sequencing and the previous studies are based on
microarray data, but the advent of next-generation
sequencing addresses some of the limitations of
microarray analysis, such as the requirement of known
genome sequence targets, limited dynamic range,
inconsistent hybridization probe properties, and the1715
Figure 5. Bar graphs showing normalized mRNA expression of SIGLEC17P and associated coding genes. We used 1-way analysis of variance to
determine significant differences between groups and the Tukey multiple comparison test to compare the difference between each pair of
means. (a) Differential gene expression in cohort I. SIGLEC17P antibody-mediated rejection (AMR) versus T cell–mediated rejection (TCMR), P ¼
0.022; AMRversus stable (STA), P ¼ 0.0007; STA 0.07125  0.03705, AMR 0.2323  0.1133, TCMR: 0.1160  0.09869. AP4S1 AMR versus TCMR, P ¼
0.031; AMR versus STA: P ¼ 0.037; STA: 0.7652  0.4108, AMR: 1.687  1.399, TCMR: 0.6691  0.5628. ZMYM6 AMR versus TCMR, P ¼ 0.0014;
AMR versus STA, P ¼ 0.0038; STA: 0.3861  0.1316, AMR: 0.9380  0.6814, TCMR: 0.2818  0.09229. USP21 AMR versus TCMR, P ¼ 0.0043; AMR
versus STA, P ¼ 0.0120; STA: 0.8361  0.3075, AMR: 1.832  1.350, TCMR: 0.6185  0.3997. DMAP1 AMR versus TCMR, P ¼ 0.0049; AMR versus
STA, P ¼ 0.0195; STA: 1.251  0.7931, AMR: 2.806  2.091, TCMR: 0.7854  0.2629. SUPT5H AMR versus TCMR, P ¼ 0.0056; AMR versus STA, P ¼
0.0017; STA: 0.6141  0.3482, AMR: 2.453  1.996, TCMR: 0.7128  0.6880. TP53BP1 AMR versus TCMR, P ¼ 0.0037; AMR versus STA, P ¼ 0.0061;
STA: 1.254  0.6196, AMR: 2.743  1.650, TCMR: 1.056  0.7488. NECAB3 AMR versus TCMR, P ¼ 0.0305; AMR versus STA, P ¼ 0.0188; STA: 3.483
 1.314, AMR: 8.225  6.061, TCMR: 3.541  2.566. BTD AMR versus TCMR, P ¼ 0.0131; AMR versus STA, P ¼ 0.0108; STA: 4.098  2.208; AMR:
15.35  15.89, TCMR: 3.554  2.415. DACT1 AMR versus TCMR, P ¼ 0.0071; AMR versus STA, P ¼ 0.0046; STA: 10.04  6.806, AMR: 69.81  75.63,
TCMR: 9.828  6.197. NCAM1 AMR versus TCMR, P ¼ 0.0154; AMR versus STA, P ¼ 0.0013; STA: 0.7785  0.3715, AMR: 4.438  3.340, TCMR:
1.540  1.667. RAB30 AMR versus TCMR, P ¼ 0.0422; AMR versus STA, P ¼ 0.0342; STA: 1.707  0.916, AMR: 3.68  2.823, TCMR: 1.644  1.351.
(b) Differential gene expression in cohort II. SIGLEC17P AMR versus STA, P ¼ 0.0296; STA: 7.618  2.855, AMR: 15.91  8.117. BTD AMR versus
STA, P ¼ 0.0334; STA: 0.2316  0.1042, AMR: 0.3905  0.1548. ZMYM6 AMR versus STA, P ¼ 0.0416; STA: 1.537  0.4455, AMR: 2.391  0.8787.
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney Rejectionhigh level of background noise caused by cross-
hybridization. Notably, RNAseq allows for higher
resolution and dynamic range and serves not only as an
additional tool for clinical diagnosis but also for an in-
depth biological assessment of the main molecular1716mechanisms and pathways involved in allograft rejec-
tion after kidney transplantation37—and even though
we are working with a small dataset and genes that
have a small effect might be lost, we found a great
number of genes previously associated with rejectionKidney International Reports (2020) 5, 1706–1721
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCHand therefore we believe in the quality of our data and
analysis. However, we used the Tempus Spin RNA
Isolation Kit (Applied Biosystems, Foster City, Califor-
nia, USA) for total RNA extraction from the blood
sample, and unfortunately small RNAs are lost using
this purification method because of the low molecular
weight cutoff from the column (approximately 200 bp).
This is why only long noncoding RNAs but no
microRNAs could be identified. There are other RNA
isolation kits that are specific for isolation of micro-
RNA, but we would have lost all the coding and long
noncoding RNAs. We chose the kit that isolates most
RNA types rather than just one kind.
Using the 3-way comparison with ENET, we found
102 genes (63 coding and 39 noncoding genes) associ-
ated with AMR (54 upregulated), TCMR (23 upregu-
lated), and STA (25 upregulated) that perfectly
clustered our samples. Using the expression of these
102 genes, we proposed 3 main clusters defined by the
genes that were upregulated within each one, and they
highly correlated with the main fundamental histologic
lesions used to classify the type of rejection. Indeed,
those genes upregulated in AMR positively correlated
with transplant glomerulopathy, microvascular
inflammation (ag and ptc), C4d deposition, and the
presence of DSA, whereas they negatively correlated
with genes upregulated in TCMR and STA. Likewise,
the histologic lesions of tubulitis, interstitial inflam-
mation defining TCMR, positively correlated with
genes upregulated in TCMR.
The biological insights under this set of genes
revealed interesting and novel data; a number of
upregulated genes in AMR are enriched in the negative
regulation of response to endoplasmic reticulum stress
GO term involving the SYVN1 and UBAC2 genes,
which have been depicted to play a role modulating the
adaptive immune response in organ transplantation by
orchestrating the synthesis, maturation, and degrada-
tion of secreted and transmembrane proteins inter-
vening during ischemia–reperfusion or rejection.20
Importantly, while RNAseq allows for the discovery
of noncoding transcripts, the functional annotation is
still poor and difficult to assess. Notably, we found 16
RP11 genes from which 11 were upregulated in rejec-
tion samples (6 in AMR and 5 in TCMR). Interestingly,
RP11 genes measured in urine have been previously
associated with TCMR and suggested as novel bio-
markers in kidney rejection.38 By inferring the func-
tionality of the noncoding genes through the
associations with the coding genes, we found that some
noncoding genes were significantly enriched in a
common GO term (regulation of transcription, DNA-
templated) and they all shared 14 overlapping coding
genes. Out of the different noncoding genes, weKidney International Reports (2020) 5, 1706–1721highlight ELF3, TADA3, TP53BP1, UP21, and
SIGLEC17P that are upregulated in AMR and con-
nected with the AKT1 and mitogen-activated protein
kinase/extracellular signal-regulated kinase
pathway.39–44 Moreover, while TP53BP1 has been
described to bind to p53 and play a key role in the
repair of double-strand DNA breaks, it has also been
shown to play a key role in Ig class-switch recombi-
nation during antibody genesis,43,44 a key feature for
DSA formation. We have inferred the noncoding genes’
functionality based on the idea of co-expression as has
been previously done by other authors,33–35 although
the fact that coding and noncoding gene are associated
does not imply a common biological function.
Another relevant finding in our study is the high
enrichment in the common GO term of the noncoding
SIGLEC17P gene in patients with AMR. SIGLEC17P
encoded by SIGLEC genes belongs to the family of
transmembrane receptors that bind sialic acid–
containing ligands. Despite being a noncoding gene,
SIGLEC17P has been shown to be highly expressed in
high levels in NK cells.41 Indeed, it is widely suggested
that the pathogenic role of NK cells participating in
AMR is caused by the enrichment of NK-related tran-
scripts found in kidney allograft tissue samples of pa-
tients undergoing AMR.45,46 Therefore, we decided to
validate the expression pattern of this pseudogene
along with its direct downstream coding genes in PB
using quantitative reverse transcription polymerase
chain reaction studies n 2 additional cohorts of kidney
transplant patients with distinct types of allograft re-
jections (TCMR, AMR, and mixed rejection as well as
STA). Interestingly, a significantly increased expres-
sion of SIGLEC17P and 9 different direct downstream
coding genes together with the NCAM/CD56 transcript
was observed in AMR compared with STA and TCMR
patients. Moreover, the selectivity of this gene was
further observed when patients with mixed rejection
were also included in the validation analysis. As
shown, this gene expression did also capture the hu-
moral pattern of these mixed phenotypes whereas it
did not in pure TCMR patients, suggesting the poten-
tial value of evaluating these genes for identifying the
type of allograft rejection and guide decision-making
regarding the type of rescue therapy.47,48
Previous studies using RNAseq in PB samples in the
field of transplantation are scarce. Dorr et al.49 first
depicted the molecular changes occurring in PB over
time in 32 stable kidney transplant patients. Kurian
et al.14 compared the molecular signatures both in PB
and tissue biopsy samples of kidney transplant patients
undergoing either clinical or subclinical TCMR using
either microarray or RNAseq platforms and showed
equivalent predictive performance between both1717
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney Rejectiontechnologies. Unlike these previous studies, we aimed
to evaluate the molecular differences between the 2
main types of rejection processes. More recently, an 8
coding-gene signature has been described in PB using
whole genome transcriptomic arrays,50 discriminating
kidney transplant patients with AMR from TCMR and
STA. We do not replicate this signature in our data as
per the design nature of our study, since we used a
multinomial model, used RNAseq, and included non-
coding genes in the analysis. Nevertheless, in the list of
genes extracted from the model (AMR vs. STA) using
only coding genes and applying the DESeq2 package,
we did find that the CXCL10 and IL15 genes were
recently reported.
To recognize the distinct molecular changes between
STA, TCMR, and AMR in PB, we carefully selected the
patients for this analysis, with paired biopsy proced-
ures at the time of the blood draw subjected to blinded
histologic diagnosis performed before the molecular
evaluation and before treatment intensification. Thus,
though these strategies increase the value of the data, it
has necessarily limited the sample numbers available
for the study. Nevertheless, to overcome this limitation
we used 2 strategies; first, we used an advanced ma-
chine learning technique, ENET, that allowed us to
study the genes in a multivariate way and to consider
the 3 clinical phenotypes (STA, AMR, and TCMR) in
the same model using a multinomial distribution, thus
overcoming the univariate methods for pairwise com-
parisons frequently used in DE analysis.51,52 Second,
we performed a permutation test to validate our results
and to make sure we were not overfitting the model.
Importantly, the characterization of the same non-
coding and coding genes in 2 additional kidney
transplant cohort confirms the validity of the data
obtained. Also, we cannot completely rule out that the
DE genes found among AMR patients compared with
TCMR and STA may also have captured the chronicity
stage of these histologic lesions because AMR patients
had a longer time of follow-up after transplantation
than TCMR and STA patients. However, it is well-
described that the main immune effector mechanism
triggering these lesions does not differ between acute
and chronic AMR, regardless the time being diag-
nosed.53 Moreover, to overcome this issue, time after
transplantation was taken into account in the multi-
nominal ENET model and it did not impact the data
obtained.
In summary, our study highlights the capacity of
RNAseq to identify robust molecular signals that can
accurately distinguish between the 2 main rejection
phenotypes in PB and highlights the important role of
specific noncoding genes in the pathophysiology of the1718distinct types of kidney allograft rejection. Additional
larger studies are highly warranted to confirm our
data and eventually use them as novel biological
markers of specific kidney rejection types to ultimately
provide guided customized immunosuppressive rescue
therapies.DISCLOSURE
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Figure S1. Heat maps showing DE genes selected by ENET
for the pairwise combination considering all rejections
(AMR þ TCMR) vs. STA for coding and noncoding genes
(A) and only coding (B). The selection is based on the
optimal alpha and lambda parameter using cross-validation.
Figure S2. Heat maps showing DE genes selected by
DESeq2 for the pairwise combination considering all
rejections (AMR þ TCMR) vs. STA for only coding genes
(A) and both coding and noncoding genes (B). The
selection is based on an FDR < 0.05 and fold-change > 1.5.
Figure S3. Heat maps showing DE genes selected by
DESeq2 for the pairwise combination considering all
rejections (AMR þ TCMR) vs. STA for only coding genes
(A) and both coding and noncoding genes (B). The
selection is based on an FDR < 0.05.
Figure S4. Heat maps showing DE genes selected by ENET
for the pairwise combination considering AMR vs. STA for
coding and noncoding genes (A) and only coding genes
(B). The selection is based on the optimal alpha and
lambda parameter using cross-validation.
Figure S5. Heat maps showing DE genes selected by
DESeq2 for the pairwise combination considering AMR
vs. STA for only coding genes (A) and both coding and
noncoding genes (B). The selection is based on an FDR <
0.05 and fold-change > 1.5.
Figure S6. HeatmapsshowingDEgenes selectedbyDESeq2
for the pairwise combination considering AMR vs. STA for
only coding genes (A) and both coding and noncoding
genes (B). The selection is based on an FDR < 0.05.
Figure S7. Heat maps showing DE genes selected by ENET
for the pairwise combination considering AMR vs. TCMR
for coding and noncoding genes (A) and only coding
genes (B). The selection is based on the optimal alpha
and lambda parameter using cross-validation.
Figure S8. Heat maps showing DE genes selected by
DESeq2 for the pairwise combination considering AMR
vs. TCMR for only coding genes (A) and both coding and
noncoding genes (B). The selection is based on an FDR <
0.05 and fold-change > 1.5.
Figure S9. Heat maps showing DE genes selected by
DESeq2 for the pairwise combination considering AMR
vs. TCMR for only coding genes (A) and both coding and
noncoding genes (B). The selection is based on an FDR <
0.05.
Figure S10. Heat map showing DE genes selected by ENET
using a multinomial distribution for only coding genes.
The selection is based on the optimal alpha and lambda
parameter using cross-validation.Kidney International Reports (2020) 5, 1706–1721Figure S11. Heat maps showing the 10 permutations with
the Jaccard index obtained from shuffling the clinical
phenotype 10 times.
Table S1. Main clinical, demographic, and histological
characteristics of patients in the validation cohorts.
Supplementary File (Excel)
Table S2. List of previously published genes differential
expressed between rejection and stable patients.
Table S3. Results of the genes associated with the clinical
outcomes for all the models applied and shown in Table 2.
Table S4. List of the 102 genes selected by ENET adjusted
by time to biopsy with the P values extracted for applying a
model per gene considering the three dummy variables
(AMR vs. TCMR, AMR vs. STA, and TCMR vs. STA)
adjusted by time to biopsy.
Table S5. List of the 1092 DE genes between rejectors
(AMR þ TCMR) vs. STA for only coding genes and the 2
lists of validation with previously published microarray
genes.
Table S6. List of genes associated (among the 102 DE
genes selected by ENET) with the different clinical and
histologic parameters with the coefficient and P value
from the linear regression model.
Table S7. List of the 529 coding–noncoding gene associa-
tions (linear regression model, FDR < 0.05) among the 102
DE genes selected by ENET.
Table S8. GO biological terms inferred to find the
functionality of the noncoding genes using the
associations established with the coding genes. Cluster
represents the clinical phenotype which the noncoding
genes is upregulated based on the DE analysis using
ENET with multinomial. Coding genes are colored if they
were used for the inferred GO term.
REFERENCES
1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J
Med. 1994;331:365–376.
2. Schnuelle P, Lorenz D, Trede M, et al. Impact of renal
cadaveric transplantation on survival in end-stage renal fail-
ure: evidence for reduced mortality risk compared with he-
modialysis during long-term follow-up. J Am Soc Nephrol.
1998;9:2135–2141.
3. Crotty S. A brief history of T cell help to B cells. Nat Rev
Immunol. 2015;15:185–189.
4. Liapis H, Gaut JP, Klein C, et al. Banff histopathological
consensus criteria for preimplantation kidney biopsies. Am J
Transplant. 2017;17:140–150.
5. Antonieta Azancot M, Moreso F, Salcedo M, et al. The
reproducibility and predictive value on outcome of renal bi-
opsies from expanded criteria donors. Kidney Int. 2014;85:
1161–1168.
6. Haas M, Segev DL, Racusen LC, et al. Arteriosclerosis in
kidneys from healthy live donors: comparison of wedge and
needle core perioperative biopsies. Arch Pathol Lab Med.
2008;132:37–42.1719
CLINICAL RESEARCH S Pineda et al.: Differential Genes by Types of Kidney Rejection7. Sigdel TK, Gao Y, He J, et al. Mining the human urine pro-
teome for monitoring renal transplant injury. Kidney Int.
2016;89:1244–1252.
8. Sigdel TK, Sarwal MM. Assessment of circulating protein
signatures for kidney transplantation in pediatric recipients.
Front Med. 2017;4:80.
9. Lefaucheur C, Loupy A. Antibody-mediated rejection of solid-
organ allografts. N Engl J Med. 2018;379:2580–2582.
10. Sarwal M, Chua M-S, Kambham N, et al. Molecular hetero-
geneity in acute renal allograft rejection identified by DNA
microarray profiling. N Engl J Med. 2003;349:125–138.
11. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-
graft B cells during renal allograft rejection. Kidney Int.
2008;74:664–673.
12. Crespo E, Cravedi P, Martorell J, et al. Posttransplant pe-
ripheral blood donor–specific interferon-g enzyme-linked
immune spot assay differentiates risk of subclinical rejec-
tion and de novo donor-specific alloantibodies in kidney
transplant recipients. Kidney Int. 2017;92:201–213.
13. Gorbacheva V, Fan R, Wang X, et al. IFN-g production by
memory helper T cells is required for CD40-independent
alloantibody responses. J Immunol. 2015;194:1347–1356.
14. Kurian SM, Williams AN, Gelbart T, et al. Molecular classifiers
for acute kidney transplant rejection in peripheral blood by
whole genome gene expression profiling. Am J Transplant.
2014;14:1164–1172.
15. Li L, Khatri P, Sigdel TK, et al. A peripheral blood diagnostic
test for acute rejection in renal transplantation. Am J Trans-
plant. 2012;12:2710–2718.
16. Kurian SM, Velazquez E, Thompson R, et al. Orthogonal
comparison of molecular signatures of kidney transplants
with subclinical and clinical acute rejection: equivalent per-
formance is agnostic to both technology and platform. Am J
Transplant. 2017;17:2103–2116.
17. Naesens M, Friedewald J, Mas V, Kaplan B, Abecassis M.
A practical guide to the clinical implementation of biomarkers
for subclinical rejection following kidney transplantation.
Transplantation. 2019;104:1.
18. Roedder S, Sigdel T, Salomonis N, et al. The kSORT assay to
detect renal transplant patients at high risk for acute rejection:
results of the multicenter AART study. PLoS Med. 2014;11:
e1001759.
19. Sigdel TK, Sarwal MM. Discovery of immune reactive human
proteins by high-density protein arrays and customized vali-
dation of potential biomarkers by ELISA. Methods Mol Biol.
2018;1788:11–21.
20. Pallet N, Fougeray S, Beaune P, et al. Endoplasmic reticulum
stress: an unrecognized actor in solid organ transplantation.
Transplantation. 2009;88:605–613.
21. Flechner SM, Kurian SM, Head SR, et al. kidney transplant
rejection and tissue injury by gene profiling of biopsies and pe-
ripheral blood lymphocytes.AmJTransplant. 2004;4:1475–1489.
22. Venner JM, Famulski KS, Badr D, et al. Molecular landscape
of T cell-mediated rejection in human kidney transplants:
prominence of CTLA4 and PD ligands. Am J Transplant.
2014;14:2565–2576.
23. Zhao S, Fung-Leung WP, Bittner A, et al. Comparison of RNA-
Seq and microarray in transcriptome profiling of activated T
cells. PloS One. 2014;9:e78644.172024. Perkins D, Verma M, Park KJ. Advances of genomic science
and systems biology in renal transplantation: a review.
Semin Immunopathol. 2011;33:211–218.
25. Mortazavi A, Williams BA, McCue K, et al. Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nat
Methods. 2008;5:621–628.
26. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney
Meeting Report: revised diagnostic criteria for chronic active
T cell-mediated rejection, antibody-mediated rejection, and
prospects for integrative endpoints for next-generation clin-
ical trials. Am J Transplant. 2018;18:293–307.
27. Love MI, Huber W, Anders S. Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2.
Genome Biol. 2014;15:550.
28. Zou H, Hastie T. Regularization and variable selection via the
elastic net (vol B 67, pg 301, 2005). J R Stat Soc B. 2005;67:
768.
29. Fruchterman TMJ, Reingold EM. Graph drawing by force-
directed placement. Software: Practice and Experience.
1991;21:1129–1164.
30. Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A
2018 reference guide to the Banff classification of renal allo-
graft pathology. Transplantation. 2018;102:1795–1814.
31. Watanabe K, Umicevic Mirkov M, de Leeuw CA, et al. Genetic
mapping of cell type specificity for complex traits. Nat Com-
mun. 2019;10:3222.
32. Watanabe K, Taskesen E, van Bochoven A, et al. Functional
mapping and annotation of genetic associations with FUMA.
Nat Commun. 2017;8:1826.
33. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of
human large intergenic noncoding RNAs reveals global prop-
erties and specific subclasses. Genes Dev. 2011;25:1915–1927.
34. Guo X, Gao L, Liao Q, et al. Long non-coding RNAs function
annotation: a global prediction method based on bi-colored
networks. Nucleic Acids Res. 2013;41:e35.
35. Liao Q, Liu C, Yuan X, et al. Large-scale prediction of long
non-coding RNA functions in a coding-non-coding gene co-
expression network. Nucleic Acids Res. 2011;39:3864–3878.
36. Menon MC, Murphy B, Heeger PS. Moving biomarkers to-
ward clinical implementation in kidney transplantation. J Am
Soc Nephrol. 2017;28:735–747.
37. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, et al.
Translating RNA sequencing into clinical diagnostics: op-
portunities and challenges. Nat Rev Genet. 2016;17:257–271.
38. Lorenzen JM, Schauerte C, Kölling M, et al. Long noncoding
RNAs in urine are detectable and may enable early detection
of acute T cell-mediated rejection of renal allografts. Clin
Chem. 2015;61:1505–1514.
39. Chen H, Chen W, Zhang X, et al. E26 transformation (ETS)
specific related transcription factor3 (ELF3) orchestrates a
positive feedback loop that constitutively activates the MAPK/
Erk pathway to drive thyroid cancer. Oncol Rep. 2019;41:570–
578.
40. Brown C, Gaspar J, Pettit A, et al. ESE-1 is a novel tran-
scriptional mediator of angiopoietin-1 expression in the
setting of inflammation. J Biol Chem. 2004;279:12794–12803.
41. Mirza S, Katafiasz BJ, Kumar R, et al. Alteration/deficiency in
activation-3 (Ada3) plays a critical role in maintaining
genomic stability. Cell Cycle. 2012;11:4266–4274.Kidney International Reports (2020) 5, 1706–1721
S Pineda et al.: Differential Genes by Types of Kidney Rejection CLINICAL RESEARCH42. Srivastava S, Mohibi S, Mirza S, et al. Epidermal growth factor
receptor activation promotes ADA3 acetylation through the
AKT-p300 pathway. Cell Cycle. 2017;16:1515–1525.
43. Li W, Cui K, Prochownik EV, et al. The deubiquitinase USP21
stabilizes MEK2 to promote tumor growth. Cell Death Dis.
2018;9:482.
44. Chen T, Hou X, Ni Y, et al. The imbalance of FOXP3/GATA3 in
regulatory T cells from the peripheral blood of asthmatic
patients. J Immunol Res. 2018;2018:3096183.
45. Einecke G, Sis B, Reeve J, et al. Antibody-mediated micro-
circulation injury is the major cause of late kidney transplant
failure. Am J Transplant. 2009;9:2520–2531.
46. Yazdani S, Callemeyn J, Gazut S, et al. Natural killer cell
infiltration is discriminative for antibody-mediated rejection
and predicts outcome after kidney transplantation. Kidney Int.
2019;95:188–198.
47. Grimbert P, Thaunat O. mTOR inhibitors and risk of chronic
antibody-mediated rejection after kidney transplantation:
where are we now? Transpl Int. 2017;30:647–657.
48. Salehi S, Sosa RA, Jin YP, et al. Outside-in HLA class I
signaling regulates ICAM-1 clustering and endothelial cell-Kidney International Reports (2020) 5, 1706–1721monocyte interactions via mTOR in transplant antibody-
mediated rejection. Am J Transplant. 2018;18:1096–1109.
49. Dorr C, Wu B, Guan W, et al. Differentially expressed gene
transcripts using RNA sequencing from the blood of immu-
nosuppressed kidney allograft recipients. PloS One. 2015;10:
e0125045.
50. Van Loon E, Gazut S, Yazdani S, et al. Development and
validation of a peripheral blood mRNA assay for the
assessment of antibody-mediated kidney allograft rejection:
a multicentre, prospective study. EBioMedicine. 2019;46:
463–472.
51. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast uni-
versal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
52. Andrews S. FastQC: a quality control tool for high throughput
sequence data. Available at: http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/FastQC. Accessed August
16, 2020.
53. Luque S, Lucia M, Melilli E, et al. Value of monitoring circu-
lating donor-reactive memory B cells to characterize
antibody-mediated rejection after kidney transplantation. Am
J Transplant. 2019;19:368–380.1721
